volume. The sales volume and prices were also severely impacted by continued weakening of international market for flat products. The Company is now gradually regaining its customer back and increasing its
95.0 22.3 Total Expenses 11,482.6 69.0 9,621.5 68.1 (1,861.2) (16.2) Profit before share of loss from investments in joint ventures, finance cost and income tax expenses 5,155.2 31.0 4,500.7 31.9 (654.5
construction contracts. The Group’s cost of construction contracts was increased to 323.55 Million Baht, comparing with last year. It was related to the increasing of revenue recognized. 3. Other revenue The
requirement by the Bank of Thailand with the capital adequacy ratio as of end of March 2021 at 16.75%. For Capital market business, the market share (SET and mai excluding proprietary trading) of Kiatnakin
of 30 September 2019, the Company has total equity amounted of THB 13,710 million which increased by THB 492 million or 4% from year ended 2018 mainly due to: 1. Registered increased share capital and
% from Baht 52,526 million in 2016 to Baht 50,114 million in 2017. The SET index at the end of 2017 closed at 1,753.71 points, increasing by 13.7% from 1,542.94 points at the end of 2016. Overall Business
decreased 4.6% from Baht 52,526 million in 2016 to Baht 50,114 million in 2017. The SET index at the end of 2017 closed at 1,753.71 points, increasing by 13.7% from 1,542.94 points at the end of 2016. Overall
31.1 34.1 Total Expenses 1,595.3 64.5 2,436.2 70.5 840.9 52.7 Profit before share of loss from investments in joint ventures, finance cost and income tax expenses 878.4 35.5 1,017.1 29.5 138.7 15.8 Share
Administrative expenses 99.0 4.8 185.6 2.8 86.7 87.6 Total Expenses 1,528.6 74.4 4,334.0 65.1 2,805.4 183.5 Profit before share of loss from investments in joint ventures, finance cost and income tax expenses
increasing from 15,000 tons per month before acquisition. With increased market share and improvement in quality, further increase in capacity utilization to 70% was planned by March 2020. Due to COVID-19